An active transport dual adaptive nanocarrier designed to overcome the corneal microenvironment for neovascularization therapy-Reference-Cited by-同舟云学术

An active transport dual adaptive nanocarrier designed to overcome the corneal microenvironment for neovascularization therapy

Published:2024 Issue:2 Volume:12 Page:361-374
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Wang Rui¹²³,Li Yingying²,Gao Shan²,Zhang Yu²,He Zhijing²,Ji Jianbo²,Yang Xiaoye²,Ye Lei²^ORCID,Zhao Lixia¹,Liu Anchang¹²³⁴,Zhai Guangxi¹²^ORCID

Affiliation:

1. Department of Pharmacy, Qilu Hospital of Shandong University, 107 Wenhua Xilu, Jinan 250012, P.R. China

2. Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P.R. China

3. Department of Pharmacy, Qilu Hospital of Shandong University (Qingdao), No. 758 Hefei Road, Qingdao, 266035, P.R. China

4. Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xilu, Jinan 250012, P.R. China

Abstract

The eyes have a complicated microenvironment with many clearance mechanisms, making it challenging for effective drug delivery to the targeted areas of the eyes.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Taishan Industry Leading Talents

National Science and Technology Major Project

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2024/BM/D3BM01349A

Reference46 articles.

1. Vesicular systems in ocular drug delivery: an overview

2. A novel and biocompatible nanofiber of VEGF peptide for enhanced corneal neovascularization suppression

3. Intrastromal bevacizumab in the management of corneal neovascularization: a retrospective review

4. Advances and limitations of drug delivery systems formulated as eye drops

5. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances